Biodel Corporation
Investor Relations Department
100 Saw Mill Road
Danbury, CT 06810
United States

Visit IR website
Sign-up for email alerts

NASDAQ: BIOD [1]	
Last Trade:	3.28
Trade Time:	3:58 PM ET May 20, 2013
Change:	0.00 (0.000%)
Day Range	3.27 - 3.40
52-Week Range	2.13 - 3.82
Volume	54,400
Market Cap. ($M)	46.717
Shares Out (M)	14.243

[1] The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Biodel Inc. is a specialty pharmaceutical company that develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. Biodel's products are created by utilizing the company's proprietary VIAdel™ technology, which enables rapid delivery of drugs into the blood through various routes of administration. Faster onset of action and non-invasive routes of delivery improve the efficacy, safety, compliance and convenience for patients.... (more)

Stock Performance

Press Releases [View all]

May 8, 2013
Biodel Reports Second Quarter Fiscal Year 2013 Financial Results

May 6, 2013
Biodel to Report Second Quarter Fiscal Year 2013 Financial Results on May 8, 2013

Mar 28, 2013
Biodel Completes Enrollment in Phase 2 Clinical Trial of Ultra-Rapid-Acting Insulin Candidate BIOD-123 for the Treatment of Diabetes

Feb 12, 2013
Biodel Reports First Quarter Fiscal Year 2013 Financial Results

Feb 6, 2013
Biodel to Report First Quarter Fiscal Year 2013 Financial Results on February 12, 2013

Events [View all]

There are no events to display at this time. Please check back later.

Financials [View all]

Dec 21, 2012
Annual Report (10-K)

Jan 28, 2013
Definitive Proxy Statement

May 13, 2013
Quarterly Report (10-Q)

Feb 14, 2013
Quarterly Report (10-Q)

Aug 14, 2012
Quarterly Report (10-Q)

Shareholder.com